Who Paid My Doc
Allison Hosack
Nurse Practitioner Arvada, CO Nurse Practitioner
NPI 1033721287 CMS profile 10899883
11324 Allendale Dr, Arvada, CO 80004
General payments
$1,219
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Allison Hosack of Arvada, CO is reported in the CMS Open Payments database as having received $1,219 across 54 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 73rd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $80 | 4 | |
| 2021 | General | $1,139 | 50 |
Beside peers
- Allison Hosack
- Nurse Practitioner median
- Middle half of Nurse Practitioner
- National median
In program year 2025, general payments to Allison Hosack were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.
Show as a table
| Year | Allison Hosack | Nurse Practitioner median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $50 | $22–$97 | $163 |
| 2020 | $0 | $40 | $16–$108 | $114 |
| 2021 | $1,139 | $135 | $40–$426 | $132 |
| 2022 | $80 | $152 | $48–$470 | $149 |
| 2023 | $0 | $166 | $54–$529 | $160 |
| 2024 | $0 | $173 | $55–$556 | $164 |
| 2025 | $0 | $174 | $55–$557 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 123 drugsPart D claims
6,524
Drug cost
$705,623
Branded share of claims
17.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 151 | $82,700 | |
| Invega Sustenna Paliperidone Palmitate | Brand | 13 | $41,517 | |
| Miebo Perfluorohexyloctane/Pf | Brand | 12 | $33,141 | |
| Trulicity Dulaglutide | Brand | 28 | $28,174 | |
| Atorvastatin Calcium | Generic | 429 | $24,123 | |
| Xarelto Rivaroxaban | Brand | 44 | $23,710 | |
| Januvia Sitagliptin Phosphate | Brand | 38 | $20,691 | |
| Pantoprazole Sodium | Generic | 156 | $18,708 | |
| Duloxetine Hcl | Generic | 216 | $18,627 | |
| Lacosamide | Generic | 18 | $18,586 |
The 10 drugs with the highest cost, of 123 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Records
54 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner in Colorado
Related records
Nurse Practitioner in Colorado
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner
Everyone recorded under this specialty, nationwide.
Doctors in Colorado
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.